$RVP

RETRACTABLE TECHNOLOGIES INC

Retractable Technologies manufactures and markets safety medical products, primarily syringes, for healthcare providers. Its injection devices are sold under the VanishPoint®, Patient Safe® and EasyPoint® brands. Most incorporate retractable needles designed to reduce needlestick injuries. VanishPoint® 1mL syringes have a low-dead-space design, while EasyPoint® needles are compatible with Luer-fitting syringes, including pre-filled syringes. The company also has other safety products under development. Retractable Technologies sells through U.S. general-line and specialty distributors, international distributors, and a national direct marketing network. Group purchasing organizations and purchasing representatives make most purchasing decisions. The company manufactures at its Little Elm, Texas facilities and also uses manufacturers in China. Its products are sold to and used by healthcare providers, with most sales historically made domestically. As of March 9, 2026, it has 201 employees, including 195 full-time employees.

0
2
0

No SEC Form 4 filings for $RVP in the last 30 days.

See all $RVP insider activity →
Med

RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2026

RETRACTABLE TECHNOLOGIES INC (RVP) filed an SEC Form 8-K — Other Events. Exhibit 99 RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2026 LITTLE ELM, TEXAS, November 16, 2026 — Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $14.1 million for the third quarter of 2026 and an operating loss of $4

Retractable Technologies, Inc. (RVP) Q3 Sales Rise 40%, Operating Loss Widens to $4.1M

Retractable Technologies (RVP) reported Q3 2026 sales of $14.1M, up 40% YoY, but operating loss widened to $4.1M. Nine-month sales were nearly flat at $28.5M, with an operating loss of $15.5M. The company attributes the quarterly sales recovery to unusual flu-season timing and notes that sustained improvement is needed.

RVP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning RVP (RETRACTABLE TECHNOLOGIES INC). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.

Recent RVP coverage spans financial news, earnings and corporate actions.

What's driving RVP

  • Losses persist, but the filing highlights improving tariff mitigation and a product-mix shift toward EasyPoint needles.

    SEC EDGAR 8-K · Nov 16, 2026

  • Revenue recovery is offset by worsening operating losses, keeping the turnaround thesis in question.

    tradingview.com · Nov 16, 2026

  • Dividend announcement may attract income‑focused buyers, creating modest buying pressure before the ex‑date and potential sell‑off after.

    seekingalpha.com · Oct 1, 2026

  • The dividend announcement provides a modest yield to preferred shareholders and may generate slight upward pressure on the stock.

    SEC EDGAR 8-K · Sep 30, 2026

  • The 120% tariffs on Chinese imports substantially increase costs for RVP, likely exerting downward pressure on profit margins despite revenue growth. The company's stock sentiment is somewhat bearish, reflecting concerns over tariff sustainability and profit margins.

    Stock Titan · Mar 28, 2026

AlphAI scores every news story that mentions RVP with an AI model for sentiment and relevance, and aggregates insider trades from RETRACTABLE TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RVP

Score
$RVPLowDividend· regular · $39.05K

RETRACTABLE TECHNOLOGIES, INC. DECLARES DIVIDENDS TO SERIES II AND III CLASS B PREFERRED STOCK SHAREHOLDERS

RETRACTABLE TECHNOLOGIES INC (RVP) filed an SEC Form 8-K — Other Events. Exhibit 99 RETRACTABLE TECHNOLOGIES, INC. DECLARES DIVIDENDS TO SERIES II AND III CLASS B PREFERRED STOCK SHAREHOLDERS LITTLE ELM, Texas, September 30, 2026 — Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has decla

120% China tariffs hit syringe maker as 2025 revenue climbs 15.8%

Retractable Technologies, Inc. reported a 15.8% increase in revenues for 2025, reaching $38.3 million, driven by higher domestic and international sales of its medical products. Despite the revenue growth, the company experienced a loss from operations of $21.2 million and incurred $1.8 million in tariff expenses, primarily due to a 120% tariff rate on products imported from China, which accounted for 62.6% of its sourcing. Management anticipates that these tariffs will continue to significantly impact the company's financial performance.

Related tickers